1
|
Romero-Tapiador S, Lacruz-Pleguezuelos B, Tolosana R, Freixer G, Daza R, Fernández-Díaz CM, Aguilar-Aguilar E, Fernández-Cabezas J, Cruz-Gil S, Molina S, Crespo MC, Laguna T, Marcos-Zambrano LJ, Vera-Rodriguez R, Fierrez J, Ramírez de Molina A, Ortega-Garcia J, Espinosa-Salinas I, Morales A, Carrillo de Santa Pau E. AI4FoodDB: a database for personalized e-Health nutrition and lifestyle through wearable devices and artificial intelligence. Database (Oxford) 2023; 2023:baad049. [PMID: 37465917 PMCID: PMC10354505 DOI: 10.1093/database/baad049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 05/24/2023] [Accepted: 06/21/2023] [Indexed: 07/20/2023]
Abstract
The increasing prevalence of diet-related diseases calls for an improvement in nutritional advice. Personalized nutrition aims to solve this problem by adapting dietary and lifestyle guidelines to the unique circumstances of each individual. With the latest advances in technology and data science, researchers can now automatically collect and analyze large amounts of data from a variety of sources, including wearable and smart devices. By combining these diverse data, more comprehensive insights of the human body and its diseases can be achieved. However, there are still major challenges to overcome, including the need for more robust data and standardization of methodologies for better subject monitoring and assessment. Here, we present the AI4Food database (AI4FoodDB), which gathers data from a nutritional weight loss intervention monitoring 100 overweight and obese participants during 1 month. Data acquisition involved manual traditional approaches, novel digital methods and the collection of biological samples, obtaining: (i) biological samples at the beginning and the end of the intervention, (ii) anthropometric measurements every 2 weeks, (iii) lifestyle and nutritional questionnaires at two different time points and (iv) continuous digital measurements for 2 weeks. To the best of our knowledge, AI4FoodDB is the first public database that centralizes food images, wearable sensors, validated questionnaires and biological samples from the same intervention. AI4FoodDB thus has immense potential for fostering the advancement of automatic and novel artificial intelligence techniques in the field of personalized care. Moreover, the collected information will yield valuable insights into the relationships between different variables and health outcomes, allowing researchers to generate and test new hypotheses, identify novel biomarkers and digital endpoints, and explore how different lifestyle, biological and digital factors impact health. The aim of this article is to describe the datasets included in AI4FoodDB and to outline the potential that they hold for precision health research. Database URL https://github.com/AI4Food/AI4FoodDB.
Collapse
Affiliation(s)
- Sergio Romero-Tapiador
- Biometrics and Data Pattern Analytics Laboratory, Universidad Autonoma de Madrid, Calle Francisco Tomas y Valiente, 11, Campus de Cantoblanco, Madrid 28049, Spain
| | - Blanca Lacruz-Pleguezuelos
- Computational Biology Group, Precision Nutrition and Cancer Research Program, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Ruben Tolosana
- Biometrics and Data Pattern Analytics Laboratory, Universidad Autonoma de Madrid, Calle Francisco Tomas y Valiente, 11, Campus de Cantoblanco, Madrid 28049, Spain
| | - Gala Freixer
- GENYAL Platform on Nutrition and Health, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Roberto Daza
- Biometrics and Data Pattern Analytics Laboratory, Universidad Autonoma de Madrid, Calle Francisco Tomas y Valiente, 11, Campus de Cantoblanco, Madrid 28049, Spain
| | - Cristina M Fernández-Díaz
- GENYAL Platform on Nutrition and Health, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Elena Aguilar-Aguilar
- GENYAL Platform on Nutrition and Health, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
- Department of Nursing and Nutrition, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Calle Tajo s/n, Villaviciosa de Odon, Madrid 28670, Spain
| | - Jorge Fernández-Cabezas
- GENYAL Platform on Nutrition and Health, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Silvia Cruz-Gil
- Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Susana Molina
- GENYAL Platform on Nutrition and Health, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Maria Carmen Crespo
- GENYAL Platform on Nutrition and Health, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Teresa Laguna
- Computational Biology Group, Precision Nutrition and Cancer Research Program, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Laura Judith Marcos-Zambrano
- Computational Biology Group, Precision Nutrition and Cancer Research Program, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Ruben Vera-Rodriguez
- Biometrics and Data Pattern Analytics Laboratory, Universidad Autonoma de Madrid, Calle Francisco Tomas y Valiente, 11, Campus de Cantoblanco, Madrid 28049, Spain
| | - Julian Fierrez
- Biometrics and Data Pattern Analytics Laboratory, Universidad Autonoma de Madrid, Calle Francisco Tomas y Valiente, 11, Campus de Cantoblanco, Madrid 28049, Spain
| | - Ana Ramírez de Molina
- GENYAL Platform on Nutrition and Health, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Javier Ortega-Garcia
- Biometrics and Data Pattern Analytics Laboratory, Universidad Autonoma de Madrid, Calle Francisco Tomas y Valiente, 11, Campus de Cantoblanco, Madrid 28049, Spain
| | - Isabel Espinosa-Salinas
- GENYAL Platform on Nutrition and Health, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| | - Aythami Morales
- Biometrics and Data Pattern Analytics Laboratory, Universidad Autonoma de Madrid, Calle Francisco Tomas y Valiente, 11, Campus de Cantoblanco, Madrid 28049, Spain
| | - Enrique Carrillo de Santa Pau
- Computational Biology Group, Precision Nutrition and Cancer Research Program, IMDEA Food Institute, CEI UAM+CSIC, Carretera de Cantoblanco, 8, Madrid 28049, Spain
| |
Collapse
|
3
|
Cruz-Gil S, Sánchez-Martínez R, Wagner-Reguero S, Stange D, Schölch S, Pape K, Ramírez de Molina A. A more physiological approach to lipid metabolism alterations in cancer: CRC-like organoids assessment. PLoS One 2019; 14:e0219944. [PMID: 31339921 PMCID: PMC6655698 DOI: 10.1371/journal.pone.0219944] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Accepted: 07/03/2019] [Indexed: 12/17/2022] Open
Abstract
Precision medicine might be the response to the recent questioning of the use of metformin as an anticancer drug in colorectal cancer (CRC). Thus, in order to establish properly its benefits, metformin application needs to be assayed on the different progression stages of CRC. In this way, intestinal organoids imply a more physiological tool, representing a new therapeutic opportunity for CRC personalized treatment to assay tumor stage-dependent drugs. The previously reported lipid metabolism-related axis, Acyl-CoA synthetases/ Stearoyl-CoA desaturase (ACSLs/SCD), stimulates colon cancer progression and metformin is able to rescue the invasive and migratory phenotype conferred to cancer cells upon this axis overexpression. Therefore, we checked ACSL/SCD axis status, its regulatory miRNAs and the effect of metformin treatment in intestinal organoids with the most common acquired mutations in a sporadic CRC (CRC-like organoids) as a model for specific and personalized treatment. Despite ACSL4 expression is upregulated progressively in CRC-like organoids, metformin is able to downregulate its expression, especially in the first two stages (I, II). Besides, organoids are clearly more sensitive in the first stage (Apc mutated) to metformin than current chemotherapeutic drugs such as fluorouracil (5-FU). Metformin performs an independent "Warburg effect" blockade to cancer progression and is able to reduce crypt stem cell markers expression such as LGR5+. These results suggest a putative increased efficiency of the use of metformin in early stages of CRC than in advanced disease.
Collapse
Affiliation(s)
- Silvia Cruz-Gil
- Molecular Oncology Group/ IMDEA Food Institute, CEI UAM + CSIC, Ctra, De Cantoblanco, Madrid, Spain
| | - Ruth Sánchez-Martínez
- Molecular Oncology Group/ IMDEA Food Institute, CEI UAM + CSIC, Ctra, De Cantoblanco, Madrid, Spain
| | - Sonia Wagner-Reguero
- Molecular Oncology Group/ IMDEA Food Institute, CEI UAM + CSIC, Ctra, De Cantoblanco, Madrid, Spain
| | - Daniel Stange
- Department of Gastrointestinal, Thoracic and Vascular Surgery, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Sebastian Schölch
- Department of Gastrointestinal, Thoracic and Vascular Surgery, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- German Cancer Consortium (DKTK), Dresden, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Kristin Pape
- Department of Gastrointestinal, Thoracic and Vascular Surgery, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Ana Ramírez de Molina
- Molecular Oncology Group/ IMDEA Food Institute, CEI UAM + CSIC, Ctra, De Cantoblanco, Madrid, Spain
| |
Collapse
|
4
|
Cruz-Gil S, Sanchez-Martinez R, Gomez de Cedron M, Martin-Hernandez R, Vargas T, Molina S, Herranz J, Davalos A, Reglero G, Ramirez de Molina A. Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic miRNAs: miR-19b-1 role. J Lipid Res 2018; 59:14-24. [PMID: 29074607 PMCID: PMC5748493 DOI: 10.1194/jlr.m076752] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Revised: 10/05/2017] [Indexed: 02/06/2023] Open
Abstract
An abnormal acyl-CoA synthetase/stearoyl-CoA desaturase (ACSL/SCD) lipid network fuels colon cancer progression, endowing cells with invasive and migratory properties. Therapies against this metabolic network may be useful to improve clinical outcomes. Because micro-RNAs (miRNAs/miRs) are important epigenetic regulators, we investigated novel miRNAs targeting this pro-tumorigenic axis; hence to be used as therapeutic or prognostic miRNAs. Thirty-one putative common miRNAs were predicted to simultaneously target the three enzymes comprising the ACSL/SCD network. Target validation by quantitative RT-PCR, Western blotting, and luciferase assays showed miR-544a, miR-142, and miR-19b-1 as major regulators of the metabolic axis, ACSL/SCD Importantly, lower miR-19b-1 expression was associated with a decreased survival rate in colorectal cancer (CRC) patients, accordingly with ACSL/SCD involvement in patient relapse. Finally, miR-19b-1 regulated the pro-tumorigenic axis, ACSL/SCD, being able to inhibit invasion in colon cancer cells. Because its expression correlated with an increased survival rate in CRC patients, we propose miR-19b-1 as a potential noninvasive biomarker of disease-free survival and a promising therapeutic miRNA in CRC.
Collapse
Affiliation(s)
- Silvia Cruz-Gil
- Molecular Oncology and Nutritional Genomics of Cancer Group, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Ruth Sanchez-Martinez
- Molecular Oncology and Nutritional Genomics of Cancer Group, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Marta Gomez de Cedron
- Molecular Oncology and Nutritional Genomics of Cancer Group, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Roberto Martin-Hernandez
- Bioinformatics Unit, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Teodoro Vargas
- Molecular Oncology and Nutritional Genomics of Cancer Group, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Susana Molina
- Molecular Oncology and Nutritional Genomics of Cancer Group, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Jesús Herranz
- Biostatistics Unit, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Alberto Davalos
- Disorders of Lipid Metabolism and Molecular Nutrition Group, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Guillermo Reglero
- Molecular Oncology and Nutritional Genomics of Cancer Group, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Ana Ramirez de Molina
- Molecular Oncology and Nutritional Genomics of Cancer Group, Instituto Madrileño de Estudios Avanzados (IMDEA) Food Institute, CEI UAM+CSIC, Madrid, Spain
| |
Collapse
|
5
|
Sánchez-Martínez R, Cruz-Gil S, Gómez de Cedrón M, Álvarez-Fernández M, Vargas T, Molina S, García B, Herranz J, Moreno-Rubio J, Reglero G, Pérez-Moreno M, Feliu J, Malumbres M, Ramírez de Molina A. A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy. Oncotarget 2016; 6:38719-36. [PMID: 26451612 PMCID: PMC4770732 DOI: 10.18632/oncotarget.5340] [Citation(s) in RCA: 101] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Accepted: 09/24/2015] [Indexed: 12/31/2022] Open
Abstract
The alterations in carbohydrate metabolism that fuel tumor growth have been extensively studied. However, other metabolic pathways involved in malignant progression, demand further understanding. Here we describe a metabolic acyl-CoA synthetase/stearoyl-CoA desaturase ACSL/SCD network causing an epithelial-mesenchymal transition (EMT) program that promotes migration and invasion of colon cancer cells. The mesenchymal phenotype produced upon overexpression of these enzymes is reverted through reactivation of AMPK signaling. Furthermore, this network expression correlates with poorer clinical outcome of stage-II colon cancer patients. Finally, combined treatment with chemical inhibitors of ACSL/SCD selectively decreases cancer cell viability without reducing normal cells viability. Thus, ACSL/SCD network stimulates colon cancer progression through conferring increased energetic capacity and invasive and migratory properties to cancer cells, and might represent a new therapeutic opportunity for colon cancer treatment.
Collapse
Affiliation(s)
- Ruth Sánchez-Martínez
- Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain
| | - Silvia Cruz-Gil
- Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain
| | - Marta Gómez de Cedrón
- Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain
| | | | - Teodoro Vargas
- Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain
| | - Susana Molina
- Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain
| | - Belén García
- Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain
| | - Jesús Herranz
- Biostatistics Unit, IMDEA Food Institute, CEI UAM+CSIC, Madrid, Spain
| | - Juan Moreno-Rubio
- Medical Oncology, La Paz University Hospital (IdiPAZ-UAM), Madrid, Spain.,Precision Oncology Laboratory (POL), Infanta Sofía University Hospital, Madrid, Spain
| | - Guillermo Reglero
- Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain
| | - Mirna Pérez-Moreno
- Epithelial Cell Biology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Jaime Feliu
- Medical Oncology, La Paz University Hospital (IdiPAZ-UAM), Madrid, Spain
| | - Marcos Malumbres
- Cell Division and Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Ana Ramírez de Molina
- Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain
| |
Collapse
|